Prevention strategies for GVHD include careful donor-recipient matching to minimize HLA mismatches and the use of prophylactic immunosuppressive regimens. The use of T-cell depletion techniques in the graft can also reduce the risk of GVHD, although this may increase the risk of infection and relapse. Ongoing research is focused on developing less toxic conditioning regimens and finding ways to selectively suppress the harmful immune responses without compromising the beneficial graft-versus-tumor effects.
